We demonstrated that, in contrast to classical opioid receptors, ACKR3 won't result in classical G protein signaling and isn't modulated through the classical prescription or analgesic opioids, including morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists like naloxone. Rather, we set up that LIH383, an ACKR3-selective subnanomolar competitor https://waltern715qpw6.blogtov.com/profile